What does this research mean for the field?

Current evidence regarding the risk of incident malignancy and cancer recurrence in rheumatoid arthritis patients treated with methotrexate is limited and inconclusive, necessitating individualized treatment decisions. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To summarize the available clinical evidence on incident cancer risk and malignancy recurrence in patients with rheumatoid arthritis treated with methotrexate.

September 3, 2026Modern Rheumatology

Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations

View Full Paper

Ask AI

Bookmark

Authors

SIS. IwataWakayama Medical University MTMasahiro TadaAin Shams University RKRyuji KoikeTokyo Medical and Dental University

Discussion

Member takes

Implication

Literature review reveals complex malignancy patterns associated with methotrexate in rheumatoid arthritis, highlighting the need for individualized clinical decisions.

Key Points

To summarize the available clinical evidence on incident cancer risk and malignancy recurrence in patients with rheumatoid arthritis treated with methotrexate.
Reviewed published meta-analyses and international observational studies assessing malignancy incidence in rheumatoid arthritis and exposure to methotrexate or tumor necrosis factor inhibitors.
Rheumatoid arthritis itself is associated with a modestly increased overall cancer risk, primarily driven by heightened rates of malignant lymphoma, alongside a reduced risk of colorectal cancer.
Evidence comparing methotrexate with tumor necrosis factor inhibitors shows no significant difference in overall malignancy risk, though an Australian report identified elevated risks for lymphoma, lung cancer, and melanoma.
Methotrexate therapy is associated with an elevated risk of cancer recurrence specifically in White patients with a prior history of non-melanoma skin cancer.

Cite This Study

Iwata et al. (2026) studied this question.

synapsesocial.com/papers/6a99352e636c6408cfa7d211 https://doi.org/10.1093/mr/roag080

View Full Paper

Ask AI

Bookmark

Implication

Literature review reveals complex malignancy patterns associated with methotrexate in rheumatoid arthritis, highlighting the need for individualized clinical decisions.

Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations

Discussion

Member takes

Implication

Key Points

Cite This Study

Methotrexate and Malignancy in Rheumatoid Arthritis: Evidence, Risks, and Clinical Considerations

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider